Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
ADmit Therapeutics logo — Identification of an early Alzheimer's disease will accelera...

ADmit Therapeutics

Identification of an early Alzheimer's disease will accelerate the identification of curative drugs

Founded 2017 Spain Spain 13 employees Series Unknown Total: $8.01M Biotechnology, Health Care +1

General Information

Company Name ADmit Therapeutics
Founded Year 2017
Location Spain Spain +1
Employees 13
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Series Unknown
Social

Get notified when ADmit Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About ADmit Therapeutics

ADmit Therapeutics is a **biotechnology** startup founded in **2017** and based in **Spain**. The company's slogan, "Identification of an early Alzheimer's disease will accelerate the identification of curative drugs," reflects its focus on developing an innovative early Alzheimer's disease diagnosis test. ADmit Therapeutics recently secured a significant **€5.40M Venture Round investment** on **19 July 2023** from a diverse group of investors including Ship2B, The European Innovation Council, Clave Capital, WA4STEAM, Lavanda Ventures, and the Alzheimer's Drug Discovery Foundation. This investment will undoubtedly support the company's efforts to revolutionize Alzheimer's disease diagnosis and potentially pave the way for the identification of curative drugs.

Taxonomy: Alzheimer's disease, diagnosis test, early detection, neurodegenerative diseases, biomedical research, Barcelona, startup, medical innovation

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round •••••• 6
Investor Investor Investor Investor
•••• •••• 		19 Jul 2023
Venture Round •••••• 1
Investor
20 Mar 2020
Grant •••••• 1
Investor
20 Mar 2020
Seed Round •••••• 1
Investor
27 Mar 2019
Seed Round •••••• 1
Investor
01 Apr 2018

ADmit Therapeutics Alternatives & Competitors

ADmit Therapeutics vs
Volk Corporation
Volk Corporation United States

Custom Identification Solutions

28 employees
Industrial, Manufacturing
ADmit Therapeutics vs
Express Identification Products
Express Identification Products United States

Identification Made Simple

25 employees
ADmit Therapeutics vs
Infordata Sistemi Srl
Infordata Sistemi Srl Italy

For Easy Identification

27 employees

FAQ About ADmit Therapeutics

Identification of an early Alzheimer's disease will accelerate the identification of curative drugs
ADmit Therapeutics was founded in 2017.
ADmit Therapeutics is headquartered in Spain.
ADmit Therapeutics operates in the following industries: Biotechnology, Health Care, Pharmaceutical.
ADmit Therapeutics has approximately 13 employees.
ADmit Therapeutics has completed 5 funding rounds, raising a total of $8.01M. The latest funding stage is Series Unknown.
Top alternatives and competitors to ADmit Therapeutics include Volk Corporation, Express Identification Products, Infordata Sistemi Srl, Glavin ID, Multicard. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ADmit Therapeutics and Volk Corporation are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors ADmit Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy